Perfluoroalkyl chemicals and the risk of developing clinical and subclinical CVD
全氟烷基化学品和发生临床和亚临床 CVD 的风险
基本信息
- 批准号:8365439
- 负责人:
- 金额:$ 39.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-15 至 2013-04-30
- 项目状态:已结题
- 来源:
- 关键词:AbdomenAcetic AcidsAcidsAddressAdultAlcohol consumptionAlkanesulfonatesAmericanAncillary StudyAnimalsAnkleAsian AmericansAtherosclerosisBehaviorBloodBlood PressureBody mass indexC-reactive proteinCalciumCardiovascular DiseasesCarpetChemical ExposureChemicalsChinese PeopleChronic Kidney FailureClinicalCohort StudiesControl GroupsCoronaryCoronary arteryCoronary heart diseaseCross-Sectional StudiesDataDiseaseEnvironmentEthnic OriginEthnic groupExposure toFiltrationFire - disastersFoodFundingFutureGenderGeneral PopulationHealthHispanicsHouseholdHumanLaboratoriesLeftLeft Ventricular MassLicensingLipidsLiteratureLongitudinal StudiesLubricantsMeasuresMedialMicroalbuminuriaNational Heart, Lung, and Blood InstituteOutcomeOutcome StudyPaperParentsParticipantPhysical ExaminationPlayPolishesProceduresProspective StudiesPublic HealthQuestionnairesRaceResearch DesignResourcesRiskRoleSamplingSerumSmokingSocietiesStrokeSulfonamidesSurveysTextTextilesThickUnited StatesUnited States National Institutes of HealthVentricularVisitWomancardiovascular disorder riskcohortcost effectivedesignfasting glucosefollow-upglomerular basement membraneindexingmenperfluorodecanoic acidperfluorohexaneperfluorooctaneperfluorooctane sulfonatepopulation basedpost gamma-globulinspreventprospectiveracial and ethnicracial/ethnic differencesurfactant
项目摘要
DESCRIPTION (provided by applicant): The overall aim of this proposal is to study the prospective association between serum levels of PFCs and the risk of developing coronary heart disease (CHD), stroke, cardiovascular disease (CVD), subclinical measures of atherosclerosis and hypertensive left ventricular changes among the participants of the of the Multi-ethnic Study of Atherosclerosis (MESA), a large, multiethnic, population-based, longitudinal cohort study with participants representing both men and women and the various racial/ethnic groups in the US, including whites, blacks, Hispanics, and Asian Americans and with up to 10 years of follow-up data. We will also evaluate gender and racial/ethnic differences in PFC exposure among Americans in this contemporary general population sample and examine if the association between PFCs and CVD vary by gender, or race/ethnicity. Ours is an ancillary study that builds upon the existing strengths and resources of the NIH-funded, parent MESA cohort study to address our multiple study aims in an efficient and cost-effective manner. In the MESA, we already have data on 1) the main study outcomes, including incident CHD, stroke, and CVD validated following standard criteria and procedures adapted from other successful studies such as the NHLBI-funded ARIC study, subclinical measures of atherosclerosis including coronary artery calcium (CAC), abdominal aortic calcium (AAC), carotid intimal-medial thickness (CIMT), low ankle-brachial index (ABI), and hypertensive left ventricular parameters including left ventricular mass, volume and mass to volume (M/V) ratio 2) detailed questionnaire, physical examination, and laboratory data on potential confounding factors such as smoking, alcohol intake, body mass index (BMI), blood pressure, fasting glucose, serum lipids, high sensitivity C-reactive protein, and several other markers. In the current study, we propose a case-cohort study nested within the MESA cohort to newly measure serum levels of perfluorooctanoic acid (PFOS), perfluorooctane sulfonate (PFOA), perfluorohexane sulfonate (PFHxS), perfluorononanoic acid (PFNA), and 7 other commonly detected PFCs, including perfluoroheptanoic acid (PFHpA), perfluorodecanoic acid (PFDA), perfluoroundecanoic acid (PFUnA), perfluorododecanoic acid (PFDoA), perflurooctane sulfanomide (PFOSA), 2-(N-ethyl-perflurooctane sulfonamido) acetic acid (Et-PFOSA-AcOH), and 2-(N-methyl-perflurooctane sulfonamide) acetic acid (Me- PFOSA-AcOH), in the baseline serum of all incident CHD (n=523), and stroke (n=224), cases and a race- stratified cohort random sample of n=1000 participants (35% white, 28% black, 22% Hispanic and 12% Chinese). This study design will allow us to examine the longitudinal associations between baseline serum PFC levels and multiple outcomes using the same "control" group as well as to make valid cross-sectional comparisons (e.g. serum PFC levels by race-ethnicity). Our study is significant because it addresses a critical barrier in the field: the lack of longitudinal studies examining the relationship between PFC exposure and the risk of clinical and subclinical measures of CVD.
PUBLIC HEALTH RELEVANCE: Perfluroalkyl chemicals (PFC) are detectable in the blood of >98% of US adults. We will study the association between blood PFCs and cardiovascular disease. If we find an association, it indirectly suggests that reducing PFCs may have a role in preventing these diseases.
描述(由申请人提供):该提案的总体目的是研究PFC的血清水平与发展冠心病(CHD)(CHD),中风,心血管疾病(CVD)的前瞻性关联多民族研究的动脉粥样硬化研究(MESA)的参与者之间的左心室变化,这是一项大型,多种族的基于人群的,纵向同伴的研究,参与者代表男人和女性,以及美国各种种族/族裔群体,在美国,包括白人,黑人,西班牙裔和亚裔美国人,以及多达10年的后续数据。我们还将评估这个当代普通人群样本中美国人PFC暴露的性别和种族/种族差异,并检查PFC和CVD之间的关联是否因性别而异,还是种族/种族。我们的是一项辅助研究,基于NIH资助的父母Mesa队列研究的现有优势和资源,旨在以有效且具有成本效益的方式解决我们的多项研究目标。在MESA中,我们已经有关于1)主要研究结果的数据,包括事件冠心病,中风和CVD,遵循标准标准验证的标准标准和从其他成功研究的程序进行了验证,例如NHLBI资助的ARIC研究,包括冠心病的亚临床测量动脉钙(CAC),腹主动脉钙(AAC),颈动脉内膜厚度(CIMT),低脚踝 - 支撑指数(ABI)和高血压左心室参数,包括左心室质量,体积和体积(M/V) )比率2)详细的问卷,体格检查和实验室数据,涉及吸烟,酒精摄入,体重指数(BMI),血压,空腹葡萄糖,血清脂质,高灵敏度C-反应蛋白以及其他几种其他几种可能的混杂因素数据标记。在当前的研究中,我们提出了一项嵌套在梅萨队列中的病例研究研究,以新测量全氟辛酸的血清水平(PFOS),全氟辛烷磺酸盐(PFOA),全氟己烷磺酸盐(PFHXS)(PFHXS),荧光酮(PFHXS),pluoronananoicic酸(PFHXS),PFRNNA)和77)和77)和7个。通常检测到的PFC,包括全氟乙酸(PFHPA),全氟二烷酸(PFDA),pluoroundecanoic酸(PFUNA),pluorodododecanoic酸,PFDOA(PFDOA) - PFOSA-ACOH)和2-(N-甲基 - 透明质酸磺胺磺酰胺)乙酸(Me- Pfosa-Acoh),在所有入射CHD的基线血清中n = 1000名参与者的种族分层队列样本(35%白色,黑色28%,22%西班牙裔和12%中文)。这项研究设计将使我们能够使用相同的“控制”组以及进行有效的横截面比较(例如,按种族种族划分的血清PFC水平)检查基线血清PFC水平与多个结果之间的纵向关联。我们的研究很重要,因为它解决了该领域的关键障碍:缺乏研究PFC暴露与CVD临床和亚临床测量风险之间关系的纵向研究。
公共卫生相关性:> 98%的美国成年人的血液中可检测到全氟烷基化学物质(PFC)。我们将研究血液PFC与心血管疾病之间的关联。如果我们找到了关联,则间接表明减少PFC可能在预防这些疾病中起作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anoop Shankar其他文献
Anoop Shankar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anoop Shankar', 18)}}的其他基金
Association among serum perfluroalkyl chemicals,chronic kidney disease and cardio
血清全氟烷基化学物质与慢性肾病和心脏病之间的关系
- 批准号:
7865359 - 财政年份:2010
- 资助金额:
$ 39.41万 - 项目类别:
Association among serum perfluroalkyl chemicals,chronic kidney disease and cardio
血清全氟烷基化学物质与慢性肾病和心脏病之间的关系
- 批准号:
8081796 - 财政年份:2010
- 资助金额:
$ 39.41万 - 项目类别:
相似国自然基金
乙酸干扰西瓜嗜酸菌生物膜形成作用机制的研究
- 批准号:32360695
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
小热休克蛋白Hsp26调控K.marxianus发酵米酸汤高产乙酸乙酯机理研究
- 批准号:32360568
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
大红浙醋酿造环境中乙醇和乙酸诱导酸居芽孢杆菌生成芳香味直链醛的分子机制
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
芳氧基链烷酸酯双加氧酶AAD-12转基因大豆耐受除草剂2,4-二氯苯氧乙酸的分子机制
- 批准号:
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:
外源氨基酸干预H.uvarum与S.cerevisiae混菌发酵产乙酸高级醇酯的机制研究
- 批准号:
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
相似海外基金
Rapid Point of Care Test to Screen Human Papillomavirus in Low-Resource Settings
在资源匮乏的环境中筛查人乳头瘤病毒的快速护理点测试
- 批准号:
10897682 - 财政年份:2023
- 资助金额:
$ 39.41万 - 项目类别:
Innovative Rapid Enabling, Affordable, point-of-Care HPV Self-Testing Strategy (I-REACH)
创新的快速、经济、即时护理 HPV 自检策略 (I-REACH)
- 批准号:
10648634 - 财政年份:2023
- 资助金额:
$ 39.41万 - 项目类别:
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
- 批准号:
10758129 - 财政年份:2023
- 资助金额:
$ 39.41万 - 项目类别:
A Hybrid Implementation-Effectiveness Trial of Game Changers for Cervical Cancer Prevention in Uganda
乌干达宫颈癌预防游戏规则改变者的混合实施-有效性试验
- 批准号:
10718609 - 财政年份:2023
- 资助金额:
$ 39.41万 - 项目类别:
Enhanced Cervical Cancer Screening Adoption and Treatment Linkage for HIV positive Women in Kenya (eCASCADE-Kenya)
加强肯尼亚艾滋病毒阳性女性的宫颈癌筛查采用和治疗联系 (eCASCADE-Kenya)
- 批准号:
10738134 - 财政年份:2023
- 资助金额:
$ 39.41万 - 项目类别: